Minerva Neurosciences (NERV) Non Operating Interest Expenses (2014)
Powered by 
Analysis
Minerva Neurosciences (NERV) Non Operating Interest Expenses (2014) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.58 Bn | 130.73 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.33 Bn | 77.33 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.43 Bn | 58.24 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.84 Bn | 52.70 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.93 Bn | 34.83 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.47 Bn | 32.16 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.39 Bn | 27.56 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Minerva Neurosciences | 210.16 Mn | 210.16 Mn | - | - |